课题基金 / 基金详情

The Role of p38 MAPK Activation in Spinal Muscular Atrophy

The Role of p38 MAPK Activation in Spinal Muscular Atrophy
p38 MAPK 激活在脊髓性肌萎缩症中的作用
批准号:
9317946
负责人:
Livio Pellizzoni
金额:
$24.0万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-04-01 至 2019-03-31

项目摘要

项目成果

Livio Pellizzoni的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 脊髓性肌萎缩症(SMA)是一种以运动神经元丢失为特征的遗传性神经退行性疾病 和骨骼肌萎缩。SMA是由存活运动神经元(SMN)普遍缺乏引起的 蛋白质和,鉴于SMN减少的程度与疾病之间已经确立的直接相关性 严重时,迄今为止大多数SMA治疗方法都集中在提高SMN的表达水平 通过多种策略。其中几种方法在临床前研究中取得了显著的成功 导致了正在进行的临床试验。然而,目前还没有有效的治疗方法来治疗SMA,它仍然是 婴儿时期最常见的基因致死原因。因此,迫切需要确定能够 可以恢复SMN水平或纠正SMA患者SMN耗竭下游的缺陷。 此外,虽然更多关于SMN在RNA处理中的核心作用的知识与 对SMA动物模型的表征极大地促进了我们对这种疾病的理解 SMA运动神经元功能障碍和死亡的确切分子和细胞事件仍然存在 难以捉摸。显然,识别导致突触功能障碍的细胞因素和途径 SMN缺乏引起的选择性神经元死亡不仅是理解疾病机制的关键 但也可能扩大SMA疗法的靶点范围,以补充SMN 上调的方法即将到来。该项目旨在描述一种新的细胞通路,该通路在 SMA,以增加我们对SMN缺陷引起的下游事件的了解 与疾病进程相关,也可能代表新的潜在治疗靶点。在一种化学品中 遗传筛选抑制SMN缺乏诱导的哺乳动物细胞表型的药物 细胞中,我们确定p38MAPK抑制剂是SMN生物学的候选修饰物。进一步的研究表明, SMN缺乏体内诱导p38MAPK激活及其药理抑制改善运动缺陷 在SMA小鼠身上。基于这些发现,我们建议在这里确定p38MAPK的确切贡献 用药理学和遗传学方法在小鼠运动功能障碍模型中的失调 SMA。在目标1中,我们将对抑制p38MAPK通路的作用进行纵向分析。 SMN缺乏引起的SMA运动系统的形态和功能异常。在目标2中,我们 将开展一系列全面的研究,以确定p38MAPK依赖的分子和细胞 可能有助于SMA病理的事件,特别强调运动神经元的机制 退化。总的来说,这些研究旨在建立p38MAPK通路的激活作为一种 SMN缺乏在疾病过程中引起的致病级联的关键成分 为其抑制作为一种新的、非SMN依赖的SMA治疗方法提供概念验证。
英文摘要
Project Summary Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease characterized by motor neuron loss and skeletal muscle atrophy. SMA is caused by ubiquitous deficiency in the survival motor neuron (SMN) protein and, given the well-established direct correlation between the degree of SMN reduction and disease severity, most SMA therapeutic approaches to date have focused on increasing the levels of SMN expression through multiple strategies. The remarkable success of several of these approaches in preclinical studies has led to ongoing clinical trials. However, no effective therapy is currently available for SMA, which remains the most common genetic cause of death in infancy. Therefore, there is an urgent need to identify treatments that can either restore SMN levels or correct the deficits downstream of SMN depletion in SMA patients. Furthermore, while greater knowledge of the central role of SMN in RNA processing combined with characterization of animal models of SMA have significantly advanced our understanding of the disease, the precise molecular and cellular events that underlie the dysfunction and death of SMA motor neurons remain elusive. Clearly, identification of cellular factors and pathways contributing to synaptic dysfunction and selective neuronal death induced by SMN deficiency is not only essential to understand disease mechanisms but may also broaden the range of targets for developing SMA therapies that can complement SMN upregulation approaches. This project aims to characterize a novel cellular pathway that is dysregulated in SMA in order to increase our understanding of the downstream events induced by SMN deficiency that are relevant to the disease process, which may also represent novel potential therapeutic targets. In a chemical genetic screen for agents that suppress cellular phenotypes induced by SMN deficiency in cultured mammalian cells, we identified p38MAPK inhibitors as candidate modifiers of SMN biology. Further studies revealed that SMN deficiency induces p38MAPK activation in vivo and its pharmacological inhibition improves motor deficits in SMA mice. Building on these findings, here we propose to determine the precise contribution of p38MAPK dysregulation to motor dysfunction using both pharmacological and genetic approaches in a mouse model of SMA. In Aim 1, we will perform a longitudinal analysis of the effects of inhibiting the p38MAPK pathway on morphological and functional abnormalities induced by SMN deficiency in the SMA motor system. In Aim 2, we will carry out a comprehensive set of studies to determine the p38MAPK-dependent molecular and cellular events that may contribute to SMA pathology, with a particular emphasis on the mechanisms of motor neuron degeneration. Collectively, these studies are designed to establish activation of the p38MAPK pathway as a key component of the pathogenic cascade induced by SMN deficiency during the disease process and to provide proof-of-concept for its inhibition as a novel, SMN-independent therapeutic approach for SMA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and therapeutic targeting of motor neuron death in SMA
Mechanisms and therapeutic targeting of motor neuron death in SMA
Mechanisms and therapeutic targeting of motor neuron death in SMA
Essential role of Stasimon in motor circuit development and disease
海外基金